Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...

A group often forgotten about in the discussion of HIV – despite research pointing to an ongoing crisis – is Black women in ...

An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of ...

Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa “The arrivals of the first doses of lenacapavir ...

Citi Annual Global Healthcare Conference 2025 December 2, 2025 11:15 AM ESTCompany ParticipantsAndrew Dickinson - ...

News Is Out hosts an online panel discussion with Gilead’s Choose U ambassadors sharing stories of resilience, empowerment ...

Carlton V. Bell II won second place in GLAAD + STARZ TV Pilot Pitch Competition with a series that will destigmatize HIV.

Dec. 1 is World AIDS Day, but for the first time in decades, the federal government is not recognizing it. One metro Atlanta ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as ...

South Africa, Eswatini and Zambia on Monday began administering a groundbreaking HIV-prevention injection in the drug's first ...